Evidence map›Paper›PMID 29255058›Full record

ArticleJournal of the American Society of Nephrology : JASN2018

Dynamic Prognostic Score to Predict Kidney Allograft Survival in Patients with Antibody-Mediated Rejection.

Denis Viglietti, Alexandre Loupy, Olivier Aubert, Oriol Bestard, Jean-Paul Duong Van Huyen, Jean-Luc Taupin, Denis Glotz, Christophe Legendre, Xavier Jouven, Michel Delahousse and 2 more

Open access · bronzeAbstract readValidation Study
In one paragraph

Article in Journal of the American Society of Nephrology : JASN, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed, 1 pooled it
5.2field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

25 citing papers in PubMed, 1 synthesis or guideline pooled it, 58 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Article
  5. Article
  6. High-dimensional profiling of immune responses to kidney transplant reveals heterogeneous T helper 1 and B cell effectors associated with rejection.American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons · 2025
    Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Renal allograft DARCness in subclinical acute and chronic active ABMR.Transplant international : official journal of the European Society for Organ Transplantation · 2021
    Article
  17. Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

12 authors at 4 institutions in 2 countries.

Denis VigliettiParis Translational Research Center for Organ Transplantation, Institut National de la Santé et de la Recherche Médicale, Unité Mixte de Recherche S970, Paris, France.
Alexandre LoupyParis Translational Research Center for Organ Transplantation, Institut National de la Santé et de la Recherche Médicale, Unité Mixte de Recherche S970, Paris, France; carmen.lefaucheur@wanadoo.fr alexandreloupy@gmail.com.ORCID 0000-0003-3388-7747
Olivier AubertParis Translational Research Center for Organ Transplantation, Institut National de la Santé et de la Recherche Médicale, Unité Mixte de Recherche S970, Paris, France.
Oriol BestardDepartment of Nephrology, Bellvitge University Hospital, Barcelona, Spain.
Jean-Paul Duong Van HuyenParis Translational Research Center for Organ Transplantation, Institut National de la Santé et de la Recherche Médicale, Unité Mixte de Recherche S970, Paris, France.
Jean-Luc TaupinImmunology and Histocompatibility, Saint-Louis Hospital, Assistance Publique - Hôpitaux de Paris, Paris, France.
Denis GlotzParis Translational Research Center for Organ Transplantation, Institut National de la Santé et de la Recherche Médicale, Unité Mixte de Recherche S970, Paris, France.
Christophe LegendreParis Translational Research Center for Organ Transplantation, Institut National de la Santé et de la Recherche Médicale, Unité Mixte de Recherche S970, Paris, France.
Xavier JouvenParis Translational Research Center for Organ Transplantation, Institut National de la Santé et de la Recherche Médicale, Unité Mixte de Recherche S970, Paris, France.
Michel DelahousseDepartment of Nephrology and Kidney Transplantation, Foch Hospital, Suresnes, France.
Nassim KamarDepartment of Nephrology and Organ Transplantation, Centre Hospitalier Universtaire Rangueil, Toulouse; and.
Carmen LefaucheurParis Translational Research Center for Organ Transplantation, Institut National de la Santé et de la Recherche Médicale, Unité Mixte de Recherche S970, Paris, France; carmen.lefaucheur@wanadoo.fr alexandreloupy@gmail.com.ORCID 0000-0001-7386-6305
Translational Research in Oncology · FRInserm · FRBellvitge University Hospital · ESHôpital Foch · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

No tool is available for the early assessment of response to antibody-mediated rejection (ABMR) therapies in kidney allograft recipients. This study was designed to define a dynamic composite prognostic ABMR score to predict kidney allograft survival, integrating the disease characteristics at diagnosis and the response to treatment. Among 1978 kidney recipients who underwent transplant between 2008 and 2014, we included 278 patients diagnosed with active ABMR and receiving standard treatment, including plasma exchange, intravenous Ig, and rituximab. Patients were prospectively assessed at diagnosis and after treatment for clinical data, histologic characteristics (allograft biopsy specimen), and donor-specific anti-HLA antibodies (DSA). The dynamic ABMR prediction model included GFR (

Indexed as

Graft SurvivalKidney TransplantationAdultAllograftsAntibodiesFemaleFibrosisGlomerular Filtration RateGraft RejectionHLA AntigensHumansImmunoglobulins, IntravenousImmunologic FactorsKidneyMaleMiddle AgedAntibodiesHLA AntigensImmunoglobulins, IntravenousImmunologic FactorsRituximabkidney transplantationoutcomesrejection

Identifiers

PMID29255058
PMCPMC5791064
OpenAlexW2780003718

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.